CA2812570A1 - Formulations d'opioides a liberation controlee - Google Patents

Formulations d'opioides a liberation controlee Download PDF

Info

Publication number
CA2812570A1
CA2812570A1 CA2812570A CA2812570A CA2812570A1 CA 2812570 A1 CA2812570 A1 CA 2812570A1 CA 2812570 A CA2812570 A CA 2812570A CA 2812570 A CA2812570 A CA 2812570A CA 2812570 A1 CA2812570 A1 CA 2812570A1
Authority
CA
Canada
Prior art keywords
oxycodone
salt
opioid
pharmaceutical formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2812570A
Other languages
English (en)
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QRxPharma Ltd
Original Assignee
QRxPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd filed Critical QRxPharma Ltd
Publication of CA2812570A1 publication Critical patent/CA2812570A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2812570A 2010-09-24 2011-09-23 Formulations d'opioides a liberation controlee Abandoned CA2812570A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids
US13/024,319 2011-02-09
PCT/US2011/053132 WO2012040651A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée

Publications (1)

Publication Number Publication Date
CA2812570A1 true CA2812570A1 (fr) 2012-03-29

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2812570A Abandoned CA2812570A1 (fr) 2010-09-24 2011-09-23 Formulations d'opioides a liberation controlee

Country Status (6)

Country Link
EP (1) EP2618820A2 (fr)
JP (1) JP2013537915A (fr)
CN (1) CN103476403A (fr)
AU (1) AU2011305161A1 (fr)
CA (1) CA2812570A1 (fr)
WO (1) WO2012040651A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
EP1429739A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
WO2013153451A2 (fr) * 2012-04-09 2013-10-17 QRxPharma Ltd. Formulations d'opioïdes à libération contrôlée
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
AU2015290098B2 (en) * 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN114515282B (zh) * 2020-11-19 2023-09-08 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
EP1450824A4 (fr) * 2001-11-02 2005-09-28 Elan Corp Plc Composition pharmaceutique
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
EP1838317A4 (fr) 2005-01-05 2012-02-29 Univ Minnesota Conjugues analgesiques
WO2006103418A1 (fr) * 2005-03-28 2006-10-05 Orexo Ab Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药
AU2009203070A1 (en) * 2008-05-20 2009-12-10 Qrxpharma Limited Dual opioid pain therapy
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Also Published As

Publication number Publication date
JP2013537915A (ja) 2013-10-07
CN103476403A (zh) 2013-12-25
WO2012040651A2 (fr) 2012-03-29
EP2618820A2 (fr) 2013-07-31
WO2012040651A3 (fr) 2012-05-18
AU2011305161A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
US20110195989A1 (en) Controlled Release Formulations of Opioids
US20130022646A1 (en) Controlled Release Formulations of Opioids
CA2812570A1 (fr) Formulations d'opioides a liberation controlee
JP5844312B2 (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
RU2599846C2 (ru) Новые и эффективные лекарственые формы тапентадола
JP6550157B2 (ja) Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
US20140193490A1 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
IL235150A (en) Pharmaceuticals
EP2219612A1 (fr) Formulation à libération contrôlée évitant les utilisations impropres
CA2301883A1 (fr) Compositions contenant des unites multiples a liberation modifiee de substances medicamenteuses anti-inflammatoires non steroides (nsaid)
AU3687701A (en) Controlled-release compositions containing opioid agonist and antagonist
NO323574B1 (no) Multippelenhets doseringsmateriale for modifisert avgivelse
CA2627058A1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
MXPA04001210A (es) Formulaciones de agonista opioide con antagonista liberable y aislado.
CN107213128A (zh) 控释氢可酮制剂
EP2367541A1 (fr) Composition à libération contrôlée prévenant un mésusage
CN102365085A (zh) 具有降低的醇相互作用的抗滥用的熔体挤出制剂
WO2009088673A2 (fr) Composition pharmaceutique
AU2013204592A1 (en) Controlled release formulations of opioids
AU2018219999A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition
AU2012202717A1 (en) Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160923